| Literature DB >> 33805542 |
Katharina Witzmann1,2, Felix Raschke1,2, Esther G C Troost1,2,3,4,5.
Abstract
Radiotherapy is part of the standard treatment of most primary brain tumors. Large clinical target volumes and physical characteristics of photon beams inevitably lead to irradiation of surrounding normal brain tissue. This can cause radiation-induced brain injury. In particular, late brain injury, such as cognitive dysfunction, is often irreversible and progressive over time, resulting in a significant reduction in quality of life. Since 50% of patients have survival times greater than six months, radiation-induced side effects become more relevant and need to be balanced against radiation treatment given with curative intent. To develop adequate treatment and prevention strategies, the underlying cause of radiation-induced side-effects needs to be understood. This paper provides an overview of radiation-induced changes observed in normal-appearing brains measured with conventional and advanced MRI techniques and summarizes the current findings and conclusions. Brain atrophy was observed with anatomical MRI. Changes in tissue microstructure were seen on diffusion imaging. Vascular changes were examined with perfusion-weighted imaging and susceptibility-weighted imaging. MR spectroscopy revealed decreasing N-acetyl aspartate, indicating decreased neuronal health or neuronal loss. Based on these findings, multicenter prospective studies incorporating advanced MR techniques as well as neurocognitive function tests should be designed in order to gain more evidence on radiation-induced sequelae.Entities:
Keywords: anatomical MRI; atrophy; diffusion; functional MRI; normal-appearing brain tissue; perfusion; radiation-induced brain injuries; radiotherapy; spectroscopy
Year: 2021 PMID: 33805542 PMCID: PMC8037886 DOI: 10.3390/cancers13071573
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Publications on anatomical/morphological changes in normal-appearing tissue after radiotherapy.
| Reference | Number of Patients | Patient Age [yr] | Disease (WHO Grade) | Radiation Dose | Timing of Radiological Follow-Up | Magnetic Field Strength [T] | MRI Sequence(s) | Tissue Assessed | Main Findings/Alterations |
|---|---|---|---|---|---|---|---|---|---|
| Nagtegaal et al., 2021 [ | 31 | 50 ± 15 | G (II–IV) | 50.4–60 Gy | ≥one follow-up 270–360 d post-RT | 3 | T1w | GM structures | Atrophy in all GM structures except caudate nucleus |
| Raschke et al., 2020 [ | 91 | 52.3 ± 14.5 | G (I–IV) | 54 Gy or 60 Gy | 3, 6, 9, 12, 15, 18, 21 mo post-RT | 3 | T1w | Cerebellum | Cerebellar atrophy |
| Takeshita et al., 2020 [ | 20 | 66.2 ± 9.7 | MB | 30 Gy/10 fractions | 0–3 mo, 4–7 mo, 8–11 mo post-RT | 3 | T1w | Hippocampus | Hippocampal atrophy |
| Huynh-Le et al., 2019 [ | 52 | 19–77 | G (III–IV) | 50.4 Gy to 60 Gy | 1 y post-RT | 3 | T1w | Amygdala | Amygdala atrophy |
| Gommlich et al., 2018 [ | 26 | 24–74 | G (II, III) | >54 Gy | no uniform time intervals | 1.5 and 3 | T1w | WM, GM | WM atrophy, unchanged GM volume |
| Petr et al., 2018 [ | 57 | 54.3 ± 14.2 | GBM | 60 Gy | 3 mo and 6 mo post-RT | 3 | T1w | WM, GM | GM and WM atrophy |
| Shi et al., 2018 [ | 40 | 49.3 ± 11.6 | NPC | 12 Gy (WB) | ≥12 mo post-RT | 3 | T1w | GM | Cortical GM atrophy in left hippocampus, right pulvinar, and right middle temporal gyrus |
| Seibert et al., 2017 [ | 52 | 19–77 | primary BT | 54–60 Gy | 9–15 mo post-RT | 3 | T1w | Hippocampus | Hippocampal atrophy |
| Seibert et al., 2017 [ | 54 | 19–77 | BT | 54–60 Gy | 9–15 mo post-RT | 3 | T1w | Cerebral cortex | Cortical atrophy in entorhinal and interior parietal ROIs, not in primary cortex |
| Ailion et al., 2016 [ | 25 | 9 ± 5 | Cerebellar T | n.a. | 15 ± 5 yr post-RT | 3 | T1w | Cerebellum | Cerebellar atrophy |
| Karunamuni et al., 2016 [ | 15 | 40–77 | G (HG) | 59.4–60 Gy | 1 y post-RT | 3 | T1w | Cortex | RT dose above 28.6 Gy results in >20% probability of cortical atrophy |
| Karunamuni et al., 2015 [ | 15 | 40–77 | G (HG) | 59.4–60 Gy | 1 y post-RT | 3 | T1w | Cortex | Cortical atrophy, strongest in temporal and limbic cortex |
| Hong et al., 2015 [ | 20 | 27–83 | MBM | 30 Gy/10 fractions | 6 mo post-RT | n.a. | n.a. | Hippocampus | Hippocampal avoidance can minimize hippocampal atrophy |
| Prust et al., 2015 [ | 8 | 35–70 | GBM | 60 Gy | weekly during CRT, | 3 | T1w | WB, GM, WM, | WB and GM atrophy, unchanged WM and hippocampal volume, anterior lateral ventricle volume increase |
| Olsson et al., 2012 [ | 15 | 31–65 | HNC | 1.5–9.3 Gy | 4–10 yr post-RT | 1.5 | T1w, T2w | Hippocampus | No hippocampal atrophy compared to healthy controls |
| Liu et al., 2007 [ | 9 | 5.4–13.9 | MB | 54 Gy | 1.0–8.2 yr post diagnosis | 1.5 | T1w | Cortex | Cortical thinning |
| Reddick et al., 2005 [ | 52 | 3.5–20.0 | MB | 35–40 Gy | 0.2–7.9 yr post-RT | 1.5 | T1w, T2w, PD | WM | Less developed normal appearing WM volume compared to healthy controls |
| Nagel et al., 2004 [ | 25 | 4.8–13.0 | MB | 23.4 Gy (average risk) | 0.56 yr interval post-RT | 1.5 | radiofrequency-spoiled, fast low-angle shot, 3D sequence | Hippocampus | Right and left hippocampal atrophy |
| Reddick et al., 2003 [ | 40 | 1.7–14.8 | pediatric BT | 35.2 Gy (WB) | 2.6–15.3 yr post-RT | 1.5 | T1w, T2w, PD | WM | Association between WM atrophy and reduced IQ and attentional ability |
| Palmer et al., 2002 [ | 35 | 3.2–17.2 | MB | 23.4 Gy (average risk) | year 1–2: 3 mo interval, | 1.5 | T1w | Corpus callosum | Decline of corpus callosum areas |
| Mulhern et al., 2001 [ | 42 | <21 | MB | 49–54 Gy | ≥1 yr post-RT | 1.5 | T1w, T2w, PD | WM | WM atrophy, young age at CRT associated with worth neurocognitive performance |
| Reddick et al., 2000 [ | 26 | 3.2–16.2 | MB | 36 Gy (conventional) | mean 18.7 mo post-RT | 1.5 | T1w, T2w, PD | WM | WM atrophy |
| Mulhern et al., 1999 [ | 18 | <21 | MB | 23.4–36 Gy CRT | 3.8 ± 2.6 yr post-RT | 1.5 | T1w, T2w, PD | WM | WM atrophy after RT may partially explain changes in IQ and cognitive function |
| Reddick et al., 1998 [ | 15 | 5.6–21 | MB | 25–55 Gy (WB) | 1.2–10.6 yr post-RT | 1.5 | T1w, T2w, PD | WM, GM | WM atrophy, unchanged GM volume |
Abbreviations: Brain metastasis (BM), Brain tumor (BT), Chemoradiotherapy (CRT), Glioma (G), Glioblastoma multiforme (GBM), Grey matter (GY), high grade (HG), Head-neck cancer (HNC), Intelligence quotient (IQ), Lung cancer (LC), low grade (LG), Melanoma (M), Medulloblastoma (MB), Melanoma brain metastasis (MBM), Mean diffusivity (MD), Nasopharyngeal carcinoma (NPC), Proton density (PD), Radial diffusivity (RD), Radiotherapy (RT), T1-weighted (T1w), T2-weighted (T2w), Tumor (T), White matter (WM), Whole brain (WB). Unit: day (y), month (mo), year (yr), Gray (Gy), Tesla (T).
Figure 1Hippocampal volume loss segmented in yellow for two cases (A,B). Comparison between measurements before radiotherapy (pre-RT) and one year after radiotherapy (post-RT) shows the different level of volume decrease for high- and low-dose irradiation. Reprinted from Seibert et al. [42] with permission from Elsevier.
Publications on microstructural changes in normal-appearing tissue after radiotherapy.
| Reference | Number of Patients | Patient Age [yr] | Disease (WHO Grade) | Radiation Dose | Timing of Radiological Follow-Up | Magnetic Field Strength [T] | MRI Sequence(s) | Tissue Assessed | Main Findings/Alterations |
|---|---|---|---|---|---|---|---|---|---|
| Dünger et al., 2019 [ | 70 | 23–82 | GBM | ≤60 Gy | 3 mo intervals in 3–33 mo post-RT | 3 | DWI | WM | MD ↓ |
| Raschke et al., 2019 [ | 22 | 47.8 ± 13.9 | G | 54–60 Gy | 3, 6, 9,12,15, 18 mo post-RT | 3 | DTI, 2D FFE (T2*) | WM | MD ↓, RD ↓, AD ↓, T2* ↓ |
| Tringale et al., 2019 | 22 | 20–75 | primary BT | 50.4–60 Gy | 3, 6, 12 mo post-RT | 3 | DWI | Medial temporal lobe regions | MD ↑, FA ↓ |
| Connor et al., 2017 [ | 49 | 24–84 | G (LG, II–IV) | 40.5–60 Gy | 9–12 mo post-RT | 3 | DTI | WM tracts | MD ↑, RD ↑, FA ↓ |
| Makola et al., 2017 [ | 14 | 10.1 ± 4.1 | pediatric BT | 52.75 Gy | 3–12 mo post-surgery, | 1.5 & 3 | DTI | Corpus callosum | RD ↑, FA ↓ |
| Chapman et al., 2016 [ | 27 | 26–71 | LG/benign T | 54 Gy | pre-RT, during RT, end of RT | 3 | DTI | Parahippocampal cingulum WM | AD ↓, RD ↑ |
| Connor et al., 2016 [ | 15 | 40–84 | G (HG) | 40.05–60 Gy | 1 mo, 4–6 mo, 9–11 mo post-RT | 3 | DTI | WM | MD ↑, AD ↑, RD ↑, FA ↓ |
| Duan et al., 2016 [ | 81 | 19–65 | NPC | 66–74 Gy | <6 mo, 6–12 mo, | 3 | DTI | WM | MD ↑, FA ↓ |
| Zhu et al., 2016 [ | 33 | 25–72 | LG/benign T | 54 Gy | 6 MRI until 18 mo post-RT | 1.5 & 3 | DTI | WM fiber bundles | AD ↓, RD ↓ |
| Chawla et al., 2015 [ | 7 | 47–76 | G (HG) | 25–40 Gy | 30.43 ± 9.02 d post-RT | 3 | DTI | Hippocampus, genu corpus callosum | MD ↑, FA ↓ |
| Hope et al., 2015 [ | 18 | 33–66 | G (HG) | 60 Gy | every 2 w during RT, | 3 | DTI | WM | MD ↑, AD ↑, RD ↑ |
| Chapman et al., 2013 [ | 14 | 40–76 | metastases (primary: LC, M) | 30 Gy/37.5 Gy | end of RT, 1 mo post-RT | 3 | DTI | WM structures | FA ↓, RD ↑ |
| Xiong et al., 2013 [ | 55 | 19–71 | NPC | 66–75 Gy | 0–3 mo, 3–6 mo, 6–9 mo, | 3 | DTI | WM | AD ↓, RD ↑, FA ↓ |
| Chapman et al., 2012 [ | 10 | 25–71 | LG/benign T | 54 Gy | week 3 & 6 during RT, 10, 30, 78 w post-RT | 1.5 | DTI | Parahippocampal cingulum bundle & temporal lobe WM | AD ↓, RD ↑ |
| Nazem-Zadeh et al., 2012 [ | 12 | 53.5 | BM | 30 Gy/37.5 Gy | end of RT, 1 mo post-RT | 3 | DTI | Fiber tracts limbic circuit | MD ↑, FA ↓ |
| Wang et al., 2012 [ | 48 | 16–74 | NPC | 68–75 Gy | <6 mo, 6–12 mo, | 3 | DTI | temporal lobe | AD ↓, FA ↓ |
| Haris et al., 2008 [ | 5 | 41.6 ± 11.8 | G (II) | 54 Gy | 3, 8, 14 mo pre-RT | 1.5 | DTI | - | MD ↑, FA ↓ |
| Nagesh et al., 2008 [ | 25 | 23–75 | G (HG & LG), benign T | 50–81 Gy | 3, 10, 19, 32, 45 w post-RT | 1.5 | DTI | Genu & splenium corpus callosum | MD ↑, AD ↑, RD ↑, FA ↓ |
| Welzel et al., 2008 [ | 16 | 45–67 | small cell LC | 30 Gy | end of RT, 6 w post-RT | 1.5 | DTI, T2w | Supra- & infratentorial WM | FA ↓ |
| Qiu et al., 2007 [ | 22 | 8.1 ± 4.6 | MB | 50–55.8 Gy | 3.9 ± 2.9 yr post-RT | 1.5 | DTI | Frontal & parietal lobes | FA ↓ |
| Mabbott et al., 2006 [ | 8 | 7.5 ± 3.9 | MB | 55.4 Gy | 2.50 ± 0.72 yr post-RT | 1.5 | DTI | WM | MD ↑, FA ↓ |
| Kitahara et al., 2005 [ | 8 | 26–70 | BT, L | 30–60 Gy | 0–2 mo, 3–5 mo, 6–9 mo, | 1.5 | DTI | WM | MD ↑, FA ↓ |
| Leung et al., 2004 [ | 16 | 8.8 ± 4.6 | MB | 50–55.8 Gy | 3.1 ± 1.8 yr post-RT | 1.5 | DTI | WM | FA ↓ |
| Khong et al., 2003 [ | 9 | 3–14 | MB | 50.4–54 Gy | 1–6 yr post-RT | 1.5 | DTI | WM | FA ↓ |
Abbreviations: axial diffusivity (AD), brain metastasis (BM), brain tumor (BT), diffusion tensor imaging (DTI), diffusion weighted imaging (DWI), fractional anisotropy (FA), gradient echo (FFE), glioma (G), glioblastoma multiforme (GBM), high grade (HG), lymphoma (L), lung cancer (LC), low grade (LG), melanoma (M), medulloblastoma (MB), mean diffusivity (MD), nasopharyngeal carcinoma (NPC), radial diffusivity (RD), radiotherapy (RT), T2-weighted (T2w), effective T2 (T2*), tumor (T), white matter (WM), decrease (↓), increase (↑). Unit: day (y), month (mo), year (yr), gray (Gy), tesla (T).
Figure 2(a) Percentage changes of MD (here called
Figure 3Percentage changes from baseline in MD, FA, AD (λ‖), and RD (λ) over the time for dose-bins and different b-value measurements. All parameters show time- and dose-dependent changes. For MD, AD, and RD, the changes are most pronounced for measurements with small b-values, whereas for FA, the changes are most prominent at high b-values. Hollow points: non-significant changes, filled points: significant changes, *** p < 0.001, ** p < 0.01, * p < 0.05. Reprinted from Connor et al. [80] with permission from Elsevier.
Publications on vascular changes in normal-appearing tissue after radiotherapy.
| Reference | Number of Patients | Patient Age [yr] | Disease (WHO Grade) | Radiation Dose | Timing of Radiological Follow-Up | Magnetic Field Strength [T] | MRI Sequence | Tissue Assessed | Main Finding/Alteration |
|---|---|---|---|---|---|---|---|---|---|
| Nilsen et al., 2020 [ | 40 | 42–84 | MM, metastases from non-small cell LC | 15–25 Gy | 3, 6, 9, 12, 18 mo post-SRS | 3 | DSC | GM, WM | Microvascular CBF ↓, |
| Fahlström et al., 2018 [ | 10 | 55 ± 88 | GBM (III, IV) | 60 Gy | 3.1, 34.4, 103.3 d post-RT | 1.5 | DSC | GM, WM | WM, GM: rCBV ↓, rCBF ↓ |
| Fahlström et al., 2018 [ | 12 | 55.9 ± 10.8 | G (III, IV) | 60 Gy | 3.3, 30.6, 101.6, 185.7 d post-RT | 1.5 | DCE | GM, WM | Ktrans ↔, ve ↔ |
| Petr et al., 2018 [ | 67 | 54.9 ± 14.0 | GBM | 60 Gy | 3, 6 mo post-RT | 3 | ASL | GM, WM | GM: CBF ↓ |
| Lupo et al., 2016 [ | 17 | 25–66 | G (HG) | n.a. | 8 mo–4.5 yr post-RT | 3 | SWI | Brain | Appearance of microbleeds |
| Petr et al., 2016 [ | 24 | 54.3 ± 14.1 | GBM | 60 Gy | 3, 6, 9 mo post-RT | 3 | ASL | GM | CBF ↓ |
| Jakubovic et al., 2014 [ | 19 | ≥18 | BM | 16–24 Gy | 1 w, 1 mo post-SRS | 1.5 | DSC | GM, WM | WM, GM: rCBF↑, rCBV ↑ |
| Peters et al., 2013 [ | 7 | 13 ± 4 | MB | 29.5 Gy | 4–62 mo post-RT | 3 | SWI | Brain | SWI lesions |
| Lupo et al., 2012 [ | 25 | 29–71 | G (II–IV) | n.a. | until 20 yr post-RT | 7 | SWI | Brain | Appearance of microbleeds |
| Cao et al., 2009 [ | 10 | 25–71 | G (LG), MG, CP, benign T | 50.4–59.4 Gy | week 3, 6 during RT, | 1.5 | DCE | High-dose region brain | vp ↑, Ktrans ↑ |
| Price et al., 2007 [ | 4 | 25–49 | AA (LG) | 54 Gy | after 1st fraction, end of RT, 1, 3 mo post-RT | 3 | DSC | Periventricular WM | rCBV↓, rCBF ↓ |
| Lee et al., 2005 [ | 22 | 26–73 | G (II, IV) | 60 Gy | first 4 mo post-RT | 1.5 | DSC | WM | Recirculation phase ↓ |
| Fuss et al., 2000 [ | 25 | 28–59 | Fibrillary AA (II) | 60–66 Gy | 6 w post-RT, in 6 mo intervals | 1.5 | DSC | GM WM | GM/WM: CBV ↓ |
| Wenz et al., 1996 [ | 13 | 40–78 | Multiple intracerebral metastases, | 30–40 Gy | during and until 79 mo post-RT | 1.5 | DSC | GM WM | GM/WM: CBV ↓ |
Abbreviations: astrocytoma (AA), arterial spin labeling (ASL), brain metastasis (BM), cerebral blood flow (CBF), cerebral blood volume (CBV), cranopharyngioma (CP), dynamic contrast enhanced (DCE), dynamic susceptibility contrast (DSC), glioma (G), glioblastoma multiforme (GBM), grey matter (GM), proton (1H), high grade (HG), volume transfer constant between blood plasma and extravascular extracellular space (Ktrans), lung cancer (LC), low grade (LG), medulloblastoma (MB), meningioma (MG), malignant melanoma (MM), radiotherapy (RT), susceptibility-weighted imaging (SWI), stereotactic radiosurgery (SRS), tumor (T), volume of extravascular extracellular space (ve), fractional plasma volume (vp), white matter (WM), decrease (↓), increase (↑), no change (↔). Unit: day (y), month (mo), year (yr), gray (Gy), tesla (T).
Figure 4Appearance of microbleeds after RT. Microbleeds did not appear until two years after RT and increased in number (quadruple) three years after radiotherapy. Reprinted from Lupo et al. [108] with permission from Elsevier.
Publications on metabolic changes in normal-appearing tissue after radiotherapy.
| Reference | Number of Patients | Patient Age [yr] | Disease (Grade) | Radiation Dose | Timing of Radiological Follow-Up | Magnetic Field Strength [T] | MRS Sequence | Tissue Assessed | Main Findings/Alterations |
|---|---|---|---|---|---|---|---|---|---|
| Chawla et al., 2015 [ | 7 (4 BM, 3 LC) | 47–76 | BM & LC | BM: WBRT 30–40 Gy | 30.5 ± 9.2 d post-RT | 3 | 3D EPSI | Bilateral GM and WM substructures | NAA/Cr ↓, Cho/Cr ↑ |
| Xiong et al., 2013 [ | 55 | 19–71 | NPC | 66–75 Gy | 0–3 mo, 3–6 mo, 6–9 mo, 9–12 mo, >12 mo post-RT | 3 | 2D PRESS (LTE) | ROI in WM of bilateral temporal lobes | NAA/Cho ↓, NAA/Cr ↓ |
| Wang et al., 2012 [ | 48 | 16–74 | NPC | 68–75 Gy | 1 mo—7 yr, divided in <6 mo, 6–12 mo, >12 mo post-RT | 3 | 2D PRESS (LTE) | Three voxel regions in bilateral temporal lobe WM | NAA/Cho ↓, NAA/Cr ↓ |
| Blamek et al., 2010 [ | 2 | P1: 17 | P1: MB | P1: WBRT: 59.4 Gy (posterior fossa boost) & 30 Gy (craniospinal RT) | P1: 8 yr post-RT | n.a. | SV PRESS (STE) | P1: Voxels in cerebellum left and right; | NAA/Cr ↔, Cho/Cr ↔ |
| Sundgren et al., 2009 [ | 11 | 25–71 | G (LG), | 50.4–59.4 Gy | 3, 6 w during RT, | 1.5 | 2D PRESS (LTE) | ≥14 voxels in brain (no cerebellum or pons) | NAA/Cho ↑, NAA/Cr ↓, Cho/Cr ↓ |
| Matulewicz et al., 2006 [ | 100 | 19–74 | G (I–IV) | 60 Gy | one follow-up during 2 yr post-RT | 2 | SV PRESS (STE) | Voxels in WM | NAA/Cho ↓, Cho/Cr ↑ |
| Kaminaga et al., 2005 [ | 20 | 42–75 | LC, BC and malignant L | 40–50 Gy | 8.5 ± 4.6 d & 3.6 ± 0.5 mo post-RT | 1.5 | SV PRESS (multi-TE) | ROI in occipital lobe cortex containing WM | NAA ↓, Cho ↑ |
| Lee et al., 2004 [ | 10 | 54.7 ± 15.8 | G (IV) | 60.0 ± 6.9 Gy | end of RT, 2, 4, 6 mo post-RT | 1.5 | 3D PRESS (LTE) | Voxels with >70% WM | NAA/Cho↓, NAA/Cr ↓, NAA ↓, Cho/Cr ↑, Cho ↑ |
| Rutkowski et al., 2003 [ | 43 | 16–63 | primary glial T | 60 Gy | 9–12 mo post-RT | 2 | SV PRESS (STE) | Voxel in low-, medium- and high-dose brain | NAA/Cr ↓ |
| Chong et al., 2001 [ | 18 | 38–64 | NPC | 59.4–124.8 Gy | 3–9.6 yr post-RT | 2 | SV PRESS (STE) | Voxels in temporal lobes | NAA ↓, Cho ↔, Cr ↔ |
| Movsas et al., 2001 [ | 8 | 39–70 | LC | 30.0–37.5 Gy | 20–46 d between baseline and follow-up | 1.5 | WB MRS | Average WB | NAA ↓ |
| Virta et al., 2000 [ | 9 | 46–61 | G (AA II–III, ODG III, GBM) | 55.0–70.4 Gy | 0.5–10.5 yr post-RT | 1.5 | Multi-slice spin echo (LTE) | ROI in WM | NAA/Cho ↑, |
| Esteve et al., 1998 [ | 11 | 44 ± 11 | G (II–IV), | 60 Gy (G), | 1, 4, 8 mo post-RT | 1.5 | SV PRESS (LTE) | VOI in contralateral hemisphere | NAA/Cho ↓, NAA/Cr ↓, NAA ↓, Cho ↑ |
| Waldrop et al., 1998 [ | 70 | 2–22 | primary brain neoplasms | 40.0–67.2 Gy | n.a. | 1.5 | SV PRESS (LTE) | Voxels of right or left frontal lobe, containing WM and GM | NAA/Cho ↓, NAA/Cr ↓ |
| Usenis et al., 1995 [ | 8 | 36–67 | BT | 59–62 Gy | 0.5–13 yr post-RT | 1.5 | SV PRESS (LTE) | VOI in parietal, frontal, temporal, or cerebellar brain (high or medium dose) | NAA ↔, Cho ↔, Cr ↔ |
| Szigety et al., 1993 [ | 13 (31P) | 24–55 (31P) | G (HG & LG), Pituitary adenoma, ODG | ≤80 Gy | end of RT, 2, 4, 8, 12, 24 mo post-RT | 1.5 | SV STEAM (LTE) (1H) | Brain parenchyma (each ipsilateral high-dose and contralateral low-dose area) | NAA/Cho ↓, Cho/Cr ↑, Cho ↑ |
Abbreviations: astrocytoma (AA), breast cancer (BC), brain metastasis (BM), brain tumor (BT), chemical shift imaging (CSI), choline (Cho), creatine (Cr), echo planar spectroscopic imaging (EPSI), glioma (G), glioblastoma multiforme (GBM), grey matter (GM), proton (1H), high grade (HG), lymphoma (L), lung cancer (LC), low grade (LG), medulloblastoma (MB), magnetic resonance spectroscopy (MRS), N-acetylaspartate (NAA), nasopharyngeal carcinoma (NPC), oligodendroglioma (ODG), phosphor (31P), patient 1/2 (P1/P2), point-resolved spectroscopy (PRESS), radiotherapy (RT), stimulated echo acquisition mode (STEAM), single voxel (SV), echo time (TE), TE < 40 ms (STE), TE > 130 ms (LTE), tumor (T), whole brain (WB), whole brain radiotherapy (WBRT), white matter (WM), decrease (↓), increase (↑), no change (↔). Unit: day (y), month (mo), year (yr), gray (Gy), tesla (T).
Figure 5(a) Metabolic changes before and two months after radiotherapy. The MRS evaluation results in a decrease of NAA/Cho and NAA/Cr two months post-RT. (b) The curves show the alterations of NAA/Cr and NAA/Cho over time for the whole cohort. Reprinted from Xiong et al. [71] with permission from Elsevier.